Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Short term Debt (2016 - 2025)

Historic Short term Debt for INVO Fertility (IVF) over the last 14 years, with Q3 2025 value amounting to $4.5 million.

  • INVO Fertility's Short term Debt rose 7938.0% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 7938.0%. This contributed to the annual value of $2.5 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, INVO Fertility's Short term Debt stood at $4.5 million, which was up 7938.0% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, INVO Fertility's Short term Debt ranged from a high of $5.0 million in Q1 2025 and a low of $185458.0 during Q1 2021
  • Moreover, its 4-year median value for Short term Debt was $2.5 million (2023), whereas its average is $2.5 million.
  • Its Short term Debt has fluctuated over the past 5 years, first changed by 0.0% in 2024, then surged by 10000.0% in 2025.
  • Over the past 4 years, INVO Fertility's Short term Debt (Quarter) stood at $340539.0 in 2021, then skyrocketed by 634.13% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then skyrocketed by 79.38% to $4.5 million in 2025.
  • Its Short term Debt stands at $4.5 million for Q3 2025, versus $5.0 million for Q2 2025 and $5.0 million for Q1 2025.